RECURRENT PANCREATIC CARCINOMA
Clinical trials for RECURRENT PANCREATIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PANCREATIC CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PANCREATIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase trial is testing a combination of two drugs—guadecitabine and durvalumab—in 55 people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. Guadecitabine aims to stop cancer cell growth, while durvalumab helps the immune system atta…
Matched conditions: RECURRENT PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail targets tough pancreatic cancer
Disease control OngoingThis early-phase study tested a combination of three drugs (gemcitabine, dasatinib, and erlotinib) in 19 people with advanced pancreatic cancer that had spread or could not be removed by surgery. The main goal was to find the safest dose and look at side effects. Researchers also…
Matched conditions: RECURRENT PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a combination of two targeted drugs (vismodegib and erlotinib) with or without a standard chemotherapy drug (gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the s…
Matched conditions: RECURRENT PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Matched conditions: RECURRENT PANCREATIC CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 06:00 UTC